June 11, 2013

COTI-2 | A Potential Breakthrough Therapy for Many Cancers

2

About COTI-2

Late preclinical drug candidate discovered using CHEMSAS® - the company’s proprietary, artificial intelligence-based drug discovery technology

2

3

COTI-2 highlights

1

2

3

Potential breakthrough therapy for many cancers

Active against many cancers with mutations of the p53 gene

> 50% of all human cancers have a p53 mutation

4

Why p53 is important?

p53 is a tumour suppressing gene

A mutation of the p53 gene is the most common mutation found in human cancer cells

If mutated, cancers can develop & grow without control

5

The future of cancer treatments

COTI-2 would treat genetic mutations common in many types of cancer Most current treatments are organ specific (i.e. treatment for lung cancer,

colon cancer, etc.)

COTI-2 targets and primarily destroys tumor cells Traditional chemotherapy kills growing & dividing cells, cancer or healthy

6

COTI-2 development progress

Easily synthesized oral formulation with no stability issues

Effective alone or in combination with approved cancer drugs

In final two-species toxicity studies prior to FDA filing enabling human trials

7

When used anywhere in this presentation, whether oral or written, the words potential, expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI).

COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission.

All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation.

Disclaimer

COTI-2 | A Potential Breakthrough Therapy for Many Cancers

www.criti caloutcome.com